Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Featured News

CytoSorbents

Press Release

10 Dec '25

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for ... CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

17 Nov '25

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in ... Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

13 Nov '25

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million available and an additional extension of the interest-only period to June 30, ... CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

11 Nov '25

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with ... CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

View All News